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cAccuracy of a Novel Risk Index Combining Degree of Stenosis of the
Carotid Artery and Plaque Surface Echogenicity
Momjiam-Mayor L, Kuzmanovic I, Momjiam S, et al. Stroke 2012;43:
1260-5.
Conclusion: A new ultrasound risk index parallels the presence of
symptoms and may be a means of assessing the clinical risk of a carotid
plaque.
Summary: Thus far, prophylactic intervention for carotid artery steno-
sis is determined primarily by the severity of the degree of the stenosis.
However, stenosis severity itself in asymptomatic patients is relatively insen-
sitive in determining which patients develop neurologic symptoms. Addi-
tional variables, such as plaque morphology, may also play an important role
in occurrence of cerebrovascular events and may be predictors of ipsilateral
stoke that act independently or in concert with the degree of stenosis. The
authors developed an ultrasound risk index (RI) based on the combination
of degree of stenosis and echogenicity of the plaque surface. In this study,
the aim was to evaluate the accuracy of the RI in a cohort of consecutive
patients presenting with symptomatic or asymptomatic carotid stenosis. In
addition, the authors wished to compare this method with other well-
established parameters, including degree of stenosis alone and gray-scale
median of the plaque, for predicting potential neurologic events associated
with carotid stenosis. The authors used consecutive patients with 50% to 99%
internal carotid stenosis. Semi-automated gray scale-based color mapping
(red, yellow, and green) of the whole plaque and of its surface was pre-
formed. The surface was defined as the region located between the lumen
(level 0) and, respectively, 0.5, 1, 1.5, and 2 mm below the surface. RI was
based on the combination of the degree of stenosis and the proportion of red
color (indicating low echogenicity) on the surface or in the whole plaque.
There were 67 symptomatic and 117 asymptomatic carotid stenoses ana-
lyzed. RI values were higher among symptomatic lesions (0.46 vs 0.29; P
.001). Using receiver operating characteristic curves, RI had stronger pre-
dictive value compared with degree of stenosis or surface echogenicity alone.
In a regression model that included age, gender, degree of stenosis, surface
echogenicity, gray-scale median of the whole plaque, and RI, RI measured
within the surface region (0.5 mm from the lumen) was the only parameter
significantly associated with the presence of symptoms (odds ratio, 4.89;
95% confidence interval, 2.7-8.7; P  .0000002). RI was also the best
criteria to differentiate between symptomatic and asymptomatic stenosis (RI
value 0.36, sensitivity 78% and specificity 65%).
Comment:These authors studiedmany different parameters to predict
symptoms associated with carotid plaque, including age, gender, degree of
stenosis, surface echogenicity, gray-scale median of the whole plaque, and
RI. Of all these parameters, it is intriguing that only RI measured within the
surface region located 0.5 mm from the lumen was significantly associated
with the presence of symptoms. Unfortunately, the authors’ RI, while an
intriguing new ultrasound parameter, appears somewhat difficult to calcu-
late, and it is unknown if the data are reproducible among different centers.
It is somewhat amazing that after 30 years, it is still only the degree of
stenosis of the internal carotid artery that is an accepted parameter for
prediction of stroke secondary to internal carotid artery stenosis.
Cardiovascular Benefits and Diabetes Risks of Statin Therapy in Pri-
mary Prevention: An Analysis From the JUPITER Trial
Ridker PM, Pradhan A, MacFadyen JG, et al. Lancet 2012;380:565-71
Conclusion: The cardiovascular mortality benefits of statin therapy
exceed the potential diabetes hazard induced by statins.
Summary: Recent trial data and meta-analysis have suggested that
statins confer an increase risk for development of diabetes (Ridker PM, et al,
N Engl J Med 2008;359:2195-207; and Sattar N, et al, Lancet 2010;375:
735-42). Recognition of the increased risk of diabetes with statin therapy has
lead to questions on the balance of benefit and risk of statin drugs for primary
prevention. The authors, therefore, analyzed data from participants from the
JUPITER trial to address the balance of vascular benefits and diabetes
hazards with statin use. In the JUPITER trial, 17,603 men and women
without previous cardiovascular disease were randomly assigned to rosuvas-
tatin (20 mg/d) or placebo and were monitored for 5 years for the primary
end point of myocardial infarction, stroke, admission to the hospital for
unstable angina, arterial revascularization, or cardiovascular death. Prespeci-
fied secondary end points of the trial included venous thromboembolism,
incident of physician-reported diabetes, and all-causemortality.With respect
to diabetes development, patients were stratified on the basis of having none
or at least one of the major four risk factors for developing diabetes: metabolic
syndrome, impaired fasting glucose, body mass index 30 kg/m2, or
M
mlycated hemoglobin A1c 6%. There were 11,508 trial participants with
ne or more major diabetes risk factors. In individuals with one or more
iabetes risk factors, statin allocation was associated with a 39% reduction in
he primary end point (hazard ratio [HR], 0.61, 95% confidence interval
CI], 0.47-0.79, P .0001), a 36% reduction in venous thromboembolism
HR, 0.64; 95% CI, 0.39-1.06; P .08), a 17% reduction in total mortality
HR, 0.83; 95% CI, 0.64-1.0; P .15), and a 28% increase in diabetes (HR,
.28; 95% CI, 1.07-1.54, P .01). For those with diabetes risk factors, 134
ascular events or deaths were avoided for every 54 new cases of diabetes
iagnosed. For trial participants with no major diabetes risk factors, statin
llocation was associated with a 52% reduction in the primary end point
HR, 0.48; 95% CI, 0.33-0.68; P  .001), a 53% reduction in venous
hromboembolism (HR, 0.47; 95% CI, 0.21-1.03; P  .05), a 22% reduc-
ion in total mortality (HR, 0.78l; 95% CI, 0.59-1.03; P  .08), and no
ncrease in diabetes (HR, 0.99; 95% CI, 0.45-2.21; P  .99). In patients
ithout diabetes risk factors, 86 vascular events were avoided, with no new
ases of diabetes diagnosed. In the 486 participants in the trial who devel-
ped diabetes in the follow-up (270 on rosuvastatin vs 216 on placebo; HR,
.25, 95% CI, 1.05-1.49; P .01), the point estimate of cardiovascular risk
eduction associated with statin therapy (HR, 0.63; 95% CI, 0.25-1.06) was
onsistent with that for the trial as a whole (HR, 0.56; 95% CI, 0.46-0.69).
ompared with placebo, statin accelerated the average time to diagnosis of
iabetes by 5.4 weeks (83.3 [standard deviation, 47.8] weeks on rosuvasta-
in vs 89.7 [50.4] weeks on placebo).
Comment: Three meta-analyses were published between 2009 and
011 indicating an increase risk of type 2 diabetes in patients taking a statin
edication. In addition, intensive-dose statin therapy appeared to be asso-
iated with higher risk than lower-dose therapy (Preiss D, et al, JAMA
011;305:2556-64). This prompted the Food and Drug Administration to
ecommend safety label changes to statin drugs (http://www.FDA.gov/
rugs/drugsaftey/ucm293101.htm). This report, while confirming the in-
reased risk of diabetes in patients on statin medications, suggests that in the
etting of primary prevention, even in the face of risk factors for development
f diabetes, the use of statin medications has a favorable overall effect on
ortality and cardiovascular events, despite an increased risk of diabetes.
he authors believe the data provide reassurance for patients and physicians
ith regard to lipid-lowering agents as adjuncts to smoking sensation,
xercise, and diet in the prevention of major cardiovascular events.
hanges in Abdominal Aortic Aneurysms Rupture and Short-Term
ortality, 1995-2008: A Retrospective Observational Study
chermerhorn ML, Bensley RP, Giles KA, et al. Ann Surg 2012;256:651-8.
Conclusion: Decreases in mortality from abdominal aortic aneurysm
AAA), both from rupture and short-term repair, are likely related to the
ntroduction and expansion of endovascular aneurysm repair (EVAR).
Summary: EVAR was approved by the U.S. Food and Drug Admin-
stration in 1999 and has resulted in lower perioperative mortality and
orbidity, as documented in three large randomized trials and in the U.S.
edicare population. Decreased morbidity and mortality associated with
VAR, combined with widespread use of abdominal imaging studies, has
esulted in more aneurysms being detected than in the past and more
neurysms being repaired. The authors’ hypothesis was that increased rates
f detection and elective repair of AAA, in combination with increasing use
f EVAR, should be associated with decreased short-term AAA-related
ortality. To test their hypothesis, they identified Medicare beneficiaries
ndergoing elective AAA repair and patients hospitalized with a ruptured
AA (rAAA) from 1995 to 2008. They then calculated standardized annual
ates of AAA-related deaths from elective repair or rupture. During the study
eriod, 338,278 patients underwent intact AAA repair, and there were
9,653 patients with rAAA, of whom 47,524 underwent repair. Repairs of
ntact AAAs increased substantially in those aged 80 years (57.7 to 92.3
er 100,000, P .001) but decreased in those aged 65 to 74 years (81.8 to
8.9, P  .001). By 2008, 77% of all intact repairs and 31% of all rAAA
epairs were performedwith EVAR (P .001). Operativemortality declined
or intact repair (4.9% to 2.4%, P  .001) and for rAAA repair (44.1% to
6.3%, P  .001). Short-term AAA-related deaths decreased by more than
alf (26.1 to 12.1 per 100,000, P  .001), with the greatest decline
ccurring in those aged 80 years (53.7 to 27.3, P  .001).
Comment: The results presented here parallel those presented earlier
his year in the British Journal of Surgery (Anjum A, et al. Br J Surg
012;99:637-45) documenting overall decreasing mortality from AAA. The
urrent study focused primarily on procedurally related deaths. Use of the
edicare database, however, cannot completely dissect all of the factors that
ay be related to a decrease in AAA mortality. For example, it is certainly
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December 20121810 Abstractspossible that aneurysms discovered incidentally may be detected when a
higher proportion are potentially treated by EVAR. In addition, comorbidi-
ties in patients with incidentally discovered AAAs may be different than in
those whose AAAs were discovered on physical examination or were associ-
ated with symptoms. TheMedicare database also does not examine the effect
of decreasing smoking rates on overall AAA-related mortality. It is very
probable there are epidemiologic and procedurally related, as well as sociality
related factors, that are all contributing to a decline of mortality related to
AAA.
Common Carotid Intima-Media Thickness Measurements in Cardio-
vascular Risk Prediction: A Meta-Analysis
den Ruijter HM, Peters SA, Anderson TJ, et al. JAMA 2012;308:796-803.
Conclusion: When added to the Framingham Risk Prediction Score,
the addition of common carotid intima-media thickness (CIMT) measure-
ments only minimally improves 10-year risk prediction of first-time myocar-
dial infraction or stroke. This improvement is unlikely to be of clinical
importance.
Summary: Prediction of cardiovascular risk is a moving target. Cardio-
vascular risk prediction for asymptomatic subjects is currently performed by
incorporating risk factors into some sort of scoring equation (Berger JS, et al,
J Am Coll Cardiol 2010;55:1169-77). Of these scoring equations, the
Framingham Risk Score is among the most widely used (D’Agostino RB Sr,
et al, Circulation 2008;117:743-53). However, prediction of cardiovascular
risk with risk equations, while reasonably accurate, still needs considerable
improvement with regard to sensitivity and specificity. Hence, there is a
desire to incorporate additional risk predictors into risk score equations. One
of these potential additional predictors to improve individual cardiovascular
risk assessments has been CIMT. The current article reports a meta-analysis
of the use CIMT to determine what value CIMT adds to current risk
predictionmodels in asymptomatic patients at risk for cardiovascular disease.
The specific goal was to determine whether common carotid CIMT had
added value in 10-year risk prediction of first time myocardial infarction or
stroke above that of the Framingham Risk Score alone. The authors identi-
fied relevant studies through literature searches of databases (PubMed from
1950-June 2012 and EMBASE from 1980-June 2012) and through expert
opinion. To be included, studies must have had participants drawn from the
general population, had participants with CIMT measured at baseline, and
the individuals had to have been followed up for first time myocardial
infarction or stroke. The authors included 14 population-based cohort
studies contributing data from 45,828 individuals. Median follow-up was 11
years, during which were 4,007 first time myocardial infarctions or strokes.
The authors fitted the risk factors of the Framingham Risk Score and then
extended the model with common carotid CIMTmeasurements to estimate
absolute 10-year risks to develop a first time myocardial infarction or stroke
in both models. The C statistic of both models was similar at 0.757 (95%
confidence interval [CI], 0.749-0.764) and 0.759 (95% CI 0.752-0.766).
Net reclassification improvement with the addition of common CIMT
carotid was small (0.8%; 95% CI, 0.1%-1.6%) in patients at intermediate risk.
Net reclassification improvement was 3.6% in all individuals (95% CI,
2.7%-4.6%). There were no differences between men and women.
Comment: One must agree with the authors that the apparent mag-
nitude of benefit of adding CIMT measurements as a measure of cardiovas-
cular risk in the general population, even in patients at intermediate risk, is
unlikely to be of any significant clinical benefit at 10 years. Advocates of
CIMT measurements should point out 10 years in an asymptomatic or
low-risk population is still a relatively short period of time. It is still possible
CIMT measurements may be of some benefit if the time line is extended to
20, 30, or even more years. It also should be noted that most of the patients
analyzed in this data were Caucasian, and therefore, the data cannot be
precisely extrapolated to non-Caucasian populations. Nevertheless, despite
intense interest for many years, there still does not appear to be convincing
data that measurement of CIMT has any practical use in the day-to-day care
of patients.
Antiplatelet Drug Response Status Does Not Predict Recurrent Isch-
emic Events in Stable Cardiovascular Patients Results of the Antiplate-
let Drug Resistances and Ischemic Events Study
Reny JL, Berdague P, Poncet A, and the Antiplatelet Drug Resistances and
Ischemic Events (ADRIE) Study Group. Circulation 2012;125:3201-10.
Conclusion: For stable outpatients with cardiovascular disease, mea-
surements of antiplatelet drug responsiveness with aggregation-based assays
or specific assays have no incremental predictive value over assessment of
standard cardiovascular risk factors for recurrent major adverse cardiovascu-
lar events (MACE).
Summary: Aspirin permanently inactivates cyclooxygenase-1, with
subsequent inhibition of thromboxane A2 production. Other antiplatelet
drugs, such as clopidogrel, target platelet adenosine diphosphate amplifica-
tion through inhibition of P2Y12 receptor function. Patient responsiveness
to antiplatelet drugs is variable andmay influence cardiovascular outcomes in
a
batients treated with aspirin or clopidogrel. It has been suggested that
ssessment of the biologic function of antiplatelet drugs could be used to
uide treatment in patients with cardiovascular disease. To date, however,
he value of specific and less specific platelet function assays to predict future
ardiovascular events in patients with cardiovascular disease has not been
ssessed. The authors sought to determine the added predictive value of
pecific assays (the vasodilator phosphoprotein assay for the clopidogrel
esponse and serum thromboxane B2 for aspirin response) and aggregation-
ased assays for future cardiovascular events relative to standard predictors of
ardiovascular risk. The authors twice tested 771 stable cardiovascular
utpatients participating in the Antiplatelet Drug Resistances and Ischemic
vents (ADRIE) study. Patients were tested with specific and aggregation-
ased assays. Follow-up lasted 3 years, and 1% of patients were lost to
ollow-up. MACE were assessed during follow-up and adjudicated by an
ndependent committee. Multivariant survival analysis used relevant vari-
bles identified in univariate analysis and platelet function test results. The
rognostic value of various multivariable models was expressed with the C
ndex. The primary end point was occurrence of MACE, and MACE
ccurred in 16% of patients. Hypertension, smoking, increased age, and
levated low-density lipoprotein cholesterol were predictive of MACE oc-
urrence. The C index was 0.63 (P .001). Specific and aggregation-based
ssays of platelet function did not add significant predictive value for the
rimary end point.
Comment: Previous studies have suggested a poor biologic response to
ntiplatelet drugs can be associated with recurrence of ischemic events. The
tudy population here was different than previous studies that included acute
atients assessed early on for platelet reactivity, usually 1 month after
tarting therapy. These previous studies suggested assessment of platelet
unction might be of value in the acute patient with a cardiovascular event.
he current study, however, does not support routine platelet testing in
table cardiovascular outpatients. Assessment of standard cardiovascular risk
actors remains the standard.
egional Versus General Anesthesia for Carotid Endarterectomy: The
merican College of Surgeons National Surgical Quality Improvement
rogram Perspective
chechter MA, Shortell CK, Scarborough JE. Surgery 2012;152:309-14.
Conclusion: The type of anesthesia technique does not impact patient
utcomes after carotid endarterectomy but may influence cost of care.
Summary: The advantages and disadvantages of regional vs general
nesthesia for carotid endarterectomy continue to be debated. Some inves-
igators have found regional anesthesia associated with lower postoperative
orbidity or mortality, or both, than general anesthesia. Such studies have
een hampered by small sample size and usually retrospective analysis. The
nly large multicenter randomized controlled trial to compare general
nesthesia with regional anesthesia for carotid endarterectomy, the GALA
rial, found no difference in regional vs general anesthesia on postoperative
utcomes in carotid endarterectomy (Louis SC, et al, Lancet 2008;372:
132-42). The current article represents a slightly different approach to
nalysis of this problem and used the National Surgical Quality Improve-
ent Program (NSQIP) database in an attempt to assess the effects of
egional vs local anesthesia on outcomes of carotid endarterectomy. The
uthors compared postoperative outcomes for the American College of
urgeons NSQIP database for patients undergoing carotid endarterectomy
etween 2005 and 2009 with respect to general or regional anesthesia. They
reformed a separate analysis using a subset of propensity-matched patients.
here were 24,716 patients in the NSQIP sample who underwent carotid
ndarterectomy. The propensity-matched cohort consisted of 8050 pa-
ients. The authors found no difference in 30-day postoperative composite
ates of stroke/myocardial infarction/death based on anesthetic type. With
he matched cohort, complications also did not differ (2.8% regional vs 3.6%
eneral; P  .07). Patients receiving regional anesthesia had shorter opera-
ive times (99  36 vs 119  53 minutes; P  .001) and shorter anesthesia
imes (52 29 vs 64 37 minutes; P .001). Regional anesthetic patients
ere also more likely to be discharged the next day (77.0% vs 64.4%; P 
001).
Comment:This report really doesn’t settle the issue of regional vs local
nesthesia on outcomes after carotid endarterectomy. As the authors point
ut in their discussion, despite the use of propensity analysis, there may be
nstated variables within the NSQIP database that influence the choice of
egional vs local anesthesia and that may influence outcomes after carotid
ndarterectomy. In addition, although the data suggest regional anesthesia
s not likely to be more expensive than general anesthesia for carotid
ndarterectomy, given the limitations of the NSQIP database, it also cannot
e used to definitely state that regional anesthesia will result in overall
ecreased cost for carotid endarterectomy. The study provides some infor-
ation regarding outcomes of carotid endarterectomy from the NSQIP
atabase. However, NSQIP is not designed to investigate costs or the effects
f anesthetic type on surgical procedures. It is therefore not surprising that
n analysis of a database that was not designed to answer the questions posed
y the authors did not provide a definitive answer to the authors’ question.
